Cardiovascular Risk Stratification in Covid-19

Oregon Health and Science University1,355 enrolled

Overview

This retrospective double-cohort study seeks to: 1. Describe the cardiovascular manifestations and electrophysiological (EP) substrate in COVID-19 infection and their association with clinical outcomes; and 2. Develop a method of cardiovascular risk stratification in COVID-19

Study Type

OBSERVATIONAL

Enrollment

1,355

Conditions

Covid19 Cardiovascular Risk Factor

Eligibility

Sex: ALLMin age: 18 YearsMax age: 89 Years

Medical Language ↔ Plain English

Inclusion Criteria: * age \>=18y * available data on Covid19 test in the electronic medical record (either positive or negative) Exclusion Criteria: * no data of Covid19 test

Locations (1)

Oregon Health and Science University

Portland, Oregon, United States

Outcomes

Primary Outcomes

Number and rate of persons with cardiovascular composite outcome

Number and rate of persons with composite of all-cause death, critical care utilization (ICU bed), development of a life-threatening arrhythmia (ventricular tachycardia/ventricular fibrillation or sudden cardiac arrest), acute heart failure, myocardial infarction (STEMI, NSTEMI, or silent MI), or incident stroke, whichever comes first.

Time frame: 6 months after Covid19 test

Secondary Outcomes

Rate of all-cause death outcome

Time frame: 6 months after covid19 test

Rate of cardiac arrhythmia

Rate of any documented cardiac arrhythmia (tachy - or brady- arrhythmia)

Time frame: 6 months after covid19 test

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.